Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
52
resultados
Última actualización
17/09/2025 [06:45:00]
Resultados 25 a 50 de 52
Resumen de: EP4610654A2
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
Resumen de: CN120153256A
The present invention relates to the diagnosis and assessment of juvenile granulocytic leukemia (JMML). In particular, it relates to a method of diagnosing JMML in a subject, said method comprising: a) determining the amount of at least one biomarker present on or in hematopoietic stem and progenitor cells (HSPC) in a biological sample, said at least one biomarker being selected from the group consisting of i) Group I consisting of CD52, RAMP1, LTB, LST1, JAML, IFITM3, CD7, CD69, CD164, CD74, TNF, TFPI, DLK1, CD82, IGHM, CALCRL, RALA, SLC2A5, HSPA5, HLA-DRA, RABI1A, SELL, VAMPS, FCMR, CLEC7A, NDFIP1, CLEC9A, HCST, b) comparing the quantity determined in step a) with a reference; and c) diagnosing the JMML based on the comparison of step b). In addition, the invention also relates to a method for classifying subjects suffering from JMML as a low-risk or high-risk group of JMML. Furthermore, the invention relates to the use of at least one biomarker present on or in HSPC in a biological sample for diagnosing JMML in a subject suffering from or at risk of developing into JMML as a low-risk or high-risk group of JMML. Furthermore, the present invention relates to a kit for diagnosing JMML in a subject or classifying a subject suffering from JMML as a low-risk group or a high-risk group of JMML. Furthermore, the present invention relates to the use of an inhibitor for the treatment and/or prevention of JMML, said inhibitor specifically inhibiting at least one biomarker selected fr
Resumen de: AU2025205481A1
The present invention relates to administration speed of obinutuzumab. The present invention relates to administration speed of obinutuzumab. ul u l h e p r e s e n t i n v e n t i o n r e l a t e s t o a d m i n i s t r a t i o n s p e e d o f o b i n u t u z u m a b
Resumen de: TW202440945A
Methods of monitoring therapeutic efficacy in a subject with myelodysplastic syndrome (MDS) are provided. Also provided is a method of identifying a subject with MDS for treatment with a telomerase inhibitor, and methods of treating MDS. The methods include administering to the subject a telomerase inhibitor and assessing variant allele frequency (VAF) for one or more of the following genes: SF3B1, TET2, DNMT3A, ASXL1, and CUX1 in a biological sample obtained from the subject after administration of the telomerase inhibitor. In some cases, a 25% or more reduction in VAF identifies a subject who has an increased likelihood of benefiting from treatment with a telomerase inhibitor. In some instances, the telomerase inhibitor is imetelstat or imetelstat sodium.
Resumen de: CN119119271A
Isolated human monoclonal antibodies and related antibody-based compositions and molecules that bind to human CD38 are described. Pharmaceutical compositions comprising the human antibodies and therapeutic and diagnostic methods of using the human antibodies are also described.
Resumen de: WO2025178607A1
A method and apparatus for labeling a tissue section is provided. In certain aspects, the methods comprise labeling a tissue sample via a plurality of immunohistochemistry (IHC) assays for detection of markers for characterization of a non-Hodgkin's lymphoma. The disclosed IHC assays employ chromogen-based detection methods for improved sample efficiency and visualization of biomarkers. Further disclosed is an apparatus for carrying out the disclosed methods.
Resumen de: AU2025213596A1
Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid 5 residue positions 33 to 109 of human integrin β7. Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid 5 residue positions 33 to 109 of human integrin ß7. ug r o v i d e d i s a n a c t i v e i n g r e d i e n t o f a p h a r m a c e u t i c a l u g c o m p o s i t i o n f o r t r e a t i n g m y e l o m a p e c i f i c a l l y , p r o v i d e d i s a n a n t i b o d y w h o s e e p i t o p e i s p r e s e n t i n t h e r e g i o n o f t h e a m i n o a c i d r e s i d u e p o s i t i o n s t o o f h u m a n i n t e g r i n ß
Resumen de: US2025268941A1
The present disclosure relates to BCMA/CD19 CAR T-cell products and methods for treating relapsed or refractory BCMA+ or CD19+ malignancies.
Resumen de: US2025270254A1
The present disclosure provides a probe specifically binding to CD138, a kit and a microfluidic chip comprising the probe, and a method of diagnosing diffuse large B-cell lymphoma in a subject using the probe, the kit, or the microfluidic chip. The present disclosure also provides a method of screening the probe for diagnosing diffuse large B-cell lymphoma.
Resumen de: US2025269012A1
An oncolytic group B adenovirus suitable for treating a solid tumor (for example sarcoma, carcinoma and/or lymphoma) comprising a sequence of formula (I): 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR (I) wherein: a first transgene encodes a polypeptide comprising a target-sequence specific for a binding domain on the cells of a cell-based immunotherapy, for example bearing a (exogenous) recombinant surface expressed protein, such as a chimeric antigen receptor or an NKG2D receptor, in particular wherein the target-sequence specifically binds to said surface expressed protein (more especially the chimeric antigen receptor) on the immunotherapy cell; and a second transgene encodes a polypeptide comprising a molecule that promotes trafficking of the cell-based immunotherapy into and within the tumor.
Resumen de: AU2025217281A1
Provided herein, in some embodiments, are methods for reducing the risk of developing progressive multifocal leukemia in patients undergoing natalizumab therapy by switching to an extended interval dosing (EID) schedule. Provided herein, in some embodiments, are methods for reducing the risk of developing progressive multifocal leukemia in patients undergoing natalizumab therapy by switching to an extended interval dosing (EID) schedule. ug r o v i d e d h e r e i n , i n s o m e e m b o d i m e n t s , a r e m e t h o d s f o r r e d u c i n g t h e r i s k o f d e v e l o p i n g p r o g r e s s i v e m u l t i f o c a l l e u k e m i a i n p a t i e n t s u n d e r g o i n g n a t a l i z u m a b t h e r a p y b y u g s w i t c h i n g t o a n e x t e n d e d i n t e r v a l d o s i n g ( ) s c h e d u l e
Resumen de: US2025270193A1
The present disclosure provides compounds which are useful in the treatment of oncological disorders, more particularly arylimidamides useful in the treatment of leukemias. Exemplary compounds include an azole moiety connected to a phenoxy or pyridyloxy moiety via an alkylene chain, the phenoxy or pyridyloxy moiety attached to a benzimidamide or pyridylimidamide function.
Resumen de: WO2025176039A1
Provided are use of an IL-1α inhibitor in preparing a medicament for treating leukemia therapy-induced cardiac injury and use of an IL1R1 antagonist in preparing a medicament for treating leukemia therapy-induced cardiac injury. The present disclosure can effectively reduce cardiovascular complications and the occurrence of long-term cardiovascular adverse events in the period of leukemia treatments, thereby helping alleviate the cardiac metabolic dysfunction and cardiac dysfunction after treatment.
Resumen de: US2025269065A1
Provided herein is a gene therapy for BAG3 (B-cell Lymphoma 2-Associated Anthanogene 3), e.g., using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter, a cardiac troponin T (hTNNT2) promoter, a heat shock protein 70 (HSP70) promoter, or a ubiquitin C (UBC) promoter. The capsid may be an AAVrh.74 or AAV9 capsid or a functional variant thereof. In certain embodiments, the capsid is an AAVrh.74 capsid or functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the AAV vector, and other compositions and methods.
Resumen de: US2025268920A1
Provided is a method for treating a blood cancer in an individual in need thereof by administrating to the individual an agent that inhibits activity or expression of one or more enzymes that participate in synthesis of either or both dihydrotestosterone (DHT) or androgen receptor (AR), or an antagonist AR, or a combination of an agent and the antagonist. The methods are shown in connection with acute myeloid leukemia (AML).
Resumen de: US2025268878A1
The invention relates to the use of ferroportin inhibitor compounds of the general formula (I)for treating myelodysplastic syndromes (MDS).
Resumen de: US2025268844A1
The invention discloses novel 5-substituted 4-hydroxy-cyclopent-2-en-1-one derivatives as active compounds in pharmaceutical compositions for the treatment of cancer. The invention confers cytotoxic effects of the said compounds on ovarian, colorectal, cervical, hepatocellular, lung, bladder and breast carcinomas, melanoma, lymphoma, leukemia and myeloma malignant cells, for the inhibition of cell cycle progression at the G2/M phase, for reducing the expression of DNA replication licensing factors and for having general cancer treatment effects. It further discloses the use of the said compositions for the treatment of platinum-resistant tumors. Another aspect of the invention is the synergetic effects of these compounds with existing cancer treatment medicaments as the proteasomal inhibitors. Finally, the synthetic methods of the active compounds of the said com-positions are disclosed.
Resumen de: US2025269048A1
The present invention relates bispecific antibodies and antigen binding fragments thereof for binding to CD33 and CD7 for use in treating CD33+ CD7+ hematological malignancies, and in particular Acute Myeloid Leukaemia (AML). In particular, the present invention relates to a bispecific antibody or antigen binding fragments thereof binding to CD33 and CD7, wherein the bispecific antibody or antigen binding fragments comprises a first binding region binding to human CD33 which comprises the sequences having at least 95% sequence identity to sequences: VH SEQ ID No. 81; and VL SEQ ID No. 85, and a second binding region binding to human CD7 which comprises the a VH sequence and a VL sequence having at least 95% sequence identity to the following sequences: VH SEQ ID No. 11; VH SEQ ID No. 21; VH SEQ ID No. 31; VH SEQ ID No. 51; VH SEQ ID No. 71; VL SEQ ID No. 15; VL SEQ ID No. 25; VL SEQ ID No. 35; VL SEQ ID No. 55; and VL SEQ ID No. 75 or wherein the bispecific antibody or antigen binding fragments comprises a first binding region binding to human CD33 which comprises the sequences having at least 95% sequence identity to sequences: VH SEQ ID No. 97; and VL SEQ ID No. 101, and a second binding region binding to human CD7 which comprises the a VH sequence and a VL sequence having at least 95% sequence identity to the following sequences: VH SEQ ID No. 1; VH SEQ ID No. 51; VH SEQ ID No. 71; VL SEQ ID No. 5; VL SEQ ID No. 55; and VL SEQ ID No. 75.
Resumen de: US2025269024A1
Provided herein are methods of treating a subject who has multiple myeloma and has received an initial therapy, including a stem cell transplantation. Infusions of chimeric antigen receptor (CAR)-T cells comprising a BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×105 to 5.0×106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Resumen de: WO2025174079A1
The present invention relates to a composition comprising an anti-CD20 antibody and a PIKfyve inhibitor for preventing or treating CD20 positive cancer such as B cell lymphoma. The present invention can maximize the anticancer effect of an anti-CD20 antibody, specifically, obinutuzumab, by co-administering an anti-CD20 antibody and a PIKfyve inhibitor, which is a negative regulator of a tumor cell killing mechanism thereof. In addition, by using PIKfyve as a screening target, the present invention can rapidly identify, with high reliability, combination therapy candidate agents that can synergistically enhance the direct cell death (DCD), lysosomal membrane permeabilization (LMP), and subsequent cancer cell-killing activity of anti-CD20 antibodies.
Resumen de: US2025262299A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and lenalidomide.
Resumen de: US2025263412A1
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (HDAC6) inhibitors, and their use as therapeutics for the treatment of metabolic disorders (e.g., obesity, Diabetes), neurological disorders (e.g., Alzheimer's disease, Parkinson disease, Huntington disease), cancer (e.g., multiple myeloma, biliary tract cancer, non-small cell lung cancer, chronic lymphocytic leukemia) and other conditions related to HDAC6 activity (e.g., Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT)).
Resumen de: WO2025174079A1
The present invention relates to a composition comprising an anti-CD20 antibody and a PIKfyve inhibitor for preventing or treating CD20 positive cancer such as B cell lymphoma. The present invention can maximize the anticancer effect of an anti-CD20 antibody, specifically, obinutuzumab, by co-administering an anti-CD20 antibody and a PIKfyve inhibitor, which is a negative regulator of a tumor cell killing mechanism thereof. In addition, by using PIKfyve as a screening target, the present invention can rapidly identify, with high reliability, combination therapy candidate agents that can synergistically enhance the direct cell death (DCD), lysosomal membrane permeabilization (LMP), and subsequent cancer cell-killing activity of anti-CD20 antibodies.
Resumen de: US2025263740A1
An object of the present invention is to provide a novel non-replicating bovine leukemia virus (BLV) and a producing cell thereof. According to the present invention, there is provided a bovine leukemia virus (BLV) in which at least a part of the function of a pol gene is deficient. Also, according to the present invention, there is provided a non-replicating BLV-producing cell comprising a gene of a BLV in which at least a part of the function of a pol gene is deficient. The present invention is advantageous in that it can provide a BLV vaccine which is highly immunogenic, and is highly safe without replicating in an infected subject.
Nº publicación: US2025263440A1 21/08/2025
Solicitante:
PEPTIDREAM INC [JP]
PeptiDream Inc
Resumen de: US2025263440A1
A peptide, compound, or conjugate that can bind CD38. The CD38-binding peptide, compound, or conjugate has a sequence selected from the group consisting of SEQ ID NOs. 1-34. The CD38-binding peptides, compounds, or conjugates are useful for treating CD38-associated conditions, disorders, or diseases, such as cancer, leukemia, or myelomas.
BOPI
Sede Electrónica
